摘要
Metformin,an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes,has become the focus of intense research as a candidate anticancer agent.Here,we discuss the potential of metformin in cancer therapeutics,particularly its functions in multiple signaling pathways,including AMP-activated protein kinase,mammalian target of rapamycin,insulin-like growth factor,c-Jun N-terminal kinase/mitogen-activated protein kinase(p38 MARK),human epidermal growth factor receptor-2,and nuclear factor kappaB pathways.In addition,cutting-edge targeting of cancer stem cells by metformin is summarized.
Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple signaling pathways, including AMP-activated protein kinase, mammalian target of rapamycin, insulin-like growth factor, c-Jun N-terminal kinase/mitogen-activated protein kinase (p38 MAPK), human epidermal growth factor receptor-2, and nuclear factor kappaB pathways. In addition, cutting-edge targeting of cancer stem cells by metformin is summarized.
基金
supported by National Natural Science Foundation of China(NSFC) Key Project 81130046(to JZ)
NSFC81171993(to YL) and NSFC81272415(to YL)
Guangxi Key Projects 2013GXNSFEA053004(to JZ)
Guangxi Projects 1355004-5(to JZ) and 2012GXNSFCB053004(to YL)
Guangxi Ministry of Education 201202ZD022(to YL) and 201201ZD004(to JZ)
